MRMihaela Rădulescu

Mihaela Rădulescu

*This is an algorithmically generated author record based on publicly available information.

Mihaela Rădulescu has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hepatitis B and C Virus Reactivation Patterns in a Romanian Cohort of Patients with Chronic Lymphoproliferative Disorders

    by Violeta Molagic, Raluca Mihailescu, Catalin Tiliscan, Cristina Popescu, Ana Maria Vladareanu, Remulus Catana, Mihaela Radulescu, Victoria Arama, Stefan Sorin Arama

    Hepatitis B and C virus (HBV and HCV) reactivations have become more common following the intensive use of biological therapies for the treatment of chronic lymphoproliferative disorders (CLD). We evaluate risk factors for virus reactivation and exitus in patients diagnosed with CLD and HBV or HCV infection, undergoing rituximab-chemotherapy (R-chemo). A prospective, observational study in two tertiary-care Romanian hospitals, between December 2007 and May 2010, of patients diagnosed with CLD undergoing R-chemo. HBV and HCV serological markers, viral load, fibrosis and necroinflammation were assessed at baseline and every 3–6 months. We screened 502 patients diagnosed with CLDs (77.2% non-Hodgkin lymphomas) and enrolled 57 patients with HBV and/or HCV infection with a mean age of 61.35 ± 11.1 years. The replicative virus was HBV in 23 patients (40.3%), HCV in 33 patients (57.9%). HCV reactivation rate (15.6%) was lower than for HBV (45.5%) (p = 0.02). In univariate analysis, viral reactivation was associated with aggressive CLD (p = 0.01), HBV (p = 0.01) and lymphopenia (p = 0.02). Death was associated with aggressive CLD (p = 0.01), viral reactivation (p = 0.001) and high baseline viremia (p = 0.05). In multivariate analysis, viral reactivation was associated with lymphopenia (OR 0.05, 95% CI 0.003–0.85, p = 0.03). Risk of death was 10 times higher for patients with viral reactivation (95% CI 1.54–65.5, p = 0.01). A quarter of the infected patients were diagnosed with viral reactivation. While hepatitis C was more prevalent than hepatitis B in patients with CLD, viral reactivation was found 3 times more frequently in patients with hepatitis B than C.

    • 24 October 2014
      • Vol. 52  (2) , 91-6

    Evaluation of bacterial translocation in patients with chronic HCV infection.

    by Daniela Munteanu, Anca Negru, Mihaela Radulescu, Raluca Mihailescu, St S Arama, Victoria Arama

    The factors involved in the progression of liver disease towards decompensated cirrhosis are not completely elucidated. It seems that bacterial translocation (BT) from the gut to the systemic blood flow has an important role in the disease progression, but literature data are controversial. Our objectives were to evaluate the presence of BT in patients with chronic HCV infection and to assess the correlation between BT and liver fibrosis stages and inflammatory state. We conducted a cross-sectional study on patients with chronic HCV infection in a tertiary care hospital between January and July 2013. Blood samples were collected for aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), total cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides, platelets, lipopolysaccharide (LPS) and tumor necrosis-alpha (TNFα). Plasma LPS were measured by ELISA (Kamiya Biomedical Company Seattle, SUA) and TNFα by DIAsource ImmunoAssay (Louvain-la-Neuve, Belgium) kits. Liver fibrosis was evaluated by means of FibroMax (BioPredictive, Paris, France) in all patients. We enrolled 116 patients with CHC, with a sex ratio M/F of 0.55 and a median age of 54 (45-61) years. Most of the patients (32) had compensated cirrhosis (F4). LPS levels were higher in patients with mild fibrosis--median value of 60.34 (32-91.7) ng/mL, than in cirrhotic patients--median value 40.39 (20.2-74.4) ng/mL (p = 0.051). We found no statistical correlation between LPS levels and fibrosis (p = 0.068) or TNFα levels (p = 0.097) CONCLUSIONS: There was BT in patients with CHC but it was not correlated with liver fibrosis stages or systemic inflammation. This may suggest that LPS evaluation may not be the best technique to assess baterial translocation, but further studies are needed.


  • Open Access

    Metabolic risk factors for liver inflammation in a cohort of chronic hepatitis C patients

    by Mihaela Andreea Rădulescu, Victoria Aramă, Daniela Ioana Munteanu, Raluca Ioana Mihăilescu, Cătălin Tilişcan, Cristina Popescu, Viorica Poghirc, Irina Lăpădat, Smaranda Gliga, Sorin Ștefan Aramă, et al.

  • Clinical relevance of the plasma load of cytomegalovirus in patients infected with HIV-A survival analysis

    by Victoria Aramă, Raluca Mihăilescu, Mihaela Rădulescu, Sorin Ştefan Aramă, Adrian Streinu-Cercel, Mike Youle, CMV-HIV Study group


  • Open Access

    Metabolic features in chronic HCV infected patients

    by Mihaela Andreea Rădulescu, Victoria Aramă, Daniela Ioana Munteanu, Cristina Popescu, Raluca Mihaela Năstase, Violeta Molagic, Anca-Ruxandra Negru, Irina Lăpădat, Viorica Poghirc, Sorin Ștefan Aramă, et al.

    • 1 January 2011
      • Vol. 49  (1) , 67-73

    Reactivation of HBV infection in low grade lymphoma patient.

    by Victoria Aramă, Daniela Munteanu, Ioana Olaru, Mihaela Rădulescu, Raluca Mihăilescu, Ana-Maria Vlădăreanu, Minodora Onisâi, Anamaria Vintilescu, Camelia Dobrea, M Olariu, et al.

    Reactivation of hepatitis B virus is a complication of chronic or HBV infection in patients with malignancies, especially hematological disorders, under cytotoxic or immunosuppressive therapy. The immunosuppression favors HBV replication with the massive infection of hepatocytes. Once immunity is restored when chemotherapy therapy is discontinued, a rapid, immune-mediated destruction of the infected hepatocytes ensues, clinically manifested as hepatitis, liver failure or even death. We report a case of HBV reactivation in a patient with B cells non-Hodgkin lymphoma, with HBsAg negative and protective titre of anti-HBs, after 5 months of combined chemotherapy. Currently, there are no data to support routine pre-emptive anti-HBV therapy in patients with negative HBsAg and undetectable viremia before the initiation of chemotherapy. The case presented in this paper is included in the group of patients that is studied in LIMFOVIR Grant (convention no 41012/2007). This research grant is funded by the National Center of Programs Management, program 4 - Partnerships in Priority Fields. The grant is coordinated by the National Institute of Infectious Diseases Prof. Dr. Matei Bals, Bucharest. The grant team include also the Emergency University Hospital Bucharest, Hematology Department, the "Carol Davila" University of Medicine and Pharmacy, Bucharest, the "Victor Babeş" National Institute of Research and Development, the Institute of Electrotechnical Research, Bucharest and the Polytechnic University, Bucharest. The manager of the grant is Associated Professor dr. Victoria Aramă.


    • 1 January 2008
      • Vol. 46  (4) , 305-11

    Impact of highly active antiretroviral therapy on cytomegalovirus viraemia in the absence of specific anti-cytomegalovirus therapy.

    by Raluca Mihăilescu, Victoria Arama, Simona Paraschiv, A Streinu-Cercel, D Oţelea, Daniela Munteanu, Mihaela Iosipenco, Carmen Chiotan, Otilia Elisabeta Benea, Mariana Mărdărescu, et al.

    (1) to evaluate the effect of HAART on CMV viraemia in co-infected patients, in the absence of specific anti-CMV therapy; (2) to compare 2 molecular biology techniques for the detection and quantification of CMV-DNA in these patients. We present the preliminary data of an ongoing prospective research grant on newly diagnosed HIV seropositives, in a tertiary care hospital, during June 2006- June 2008. Clinical, virological (HIV and CMV viraemia) and immunological (CD4) screening was performed every 3 months. The CMV viraemia was performed by RoboGene Human Cytomegalovirus Quantification kit (aj Roboscreen). We retested all undetectable CMV viremia found in patients with CD4 <50/mmc, by CMV PCR kit (Qiagen Diagnostics). Both PCR reactions were performed on ABI Prism 7000 (Applied Biosystems). Up to date, our study has included 105 HIV-infected subjects, who were seropositive for anti-CMV IgG antibodies. Average follow-up was 18 months. CMV viraemia was found detectable in 21 cases at first visit and in other 5 at the second visit. 22 cases had CD4 <50/mmc, among which 14 had undetectable CMV viraemia. The results of both molecular biology techniques were widely the same. HAART was prescribed to 86% of the patients; all the patients having detectable CMV viraemia received HAART, but not any specific anti-CMV therapy. Under HAART, all the detectable CMV loads which were retested in time became undetectable at next visits, after a median of 16.5 weeks from the introduction of therapy. CMV viraemia detection was useful in early diagnosis of asymptomatic CMV infection. As opposed to transplant cases, molecular biology techniques for the detection and quantification of CMV-DNA in HIV-patients have not been standardized yet. In our study, the two kits RoboGene Human Cytomegalovirus (HCMV) Quantification kit (aj Roboscreen) and CMV PCR kit (Qiagen Diagnostics) were comparable. HAART made the reduction of CMV viral load, without any specific anti-CMV therapy. As in the case of other opportunistic infections, undetectable natural history of CMV infection seemed to have been improved by controlling HIV infection.


    • 1 January 2007
      • Vol. 45  (4) , 379-85

    Predictors of tuberculosis in acute aseptic meningitis syndrome.

    by Raluca Mihăilescu, Adriana Hristea, C Băicuş, Daniela Nae, Victoria Aramă, Ruxandra Moroti Constantinescu, Mihaela Rădulescu, Daniela Munteanu, R Tănăsescu

    Tuberculous meningitis (TBM) is a medical emergency. Early and accurate diagnosis is crucial for preventing morbidity and mortality. Our aim was to define the predictors of tuberculous rather than other causes of acute aseptic meningitis syndrome (AAMS). A retrospective study of 225 patients with AAMS admitted in a tertiary care infectious diseases center between 2001 and 2004 was performed. In order to assess the value of clinical and biological variables for the diagnosis of TBM, we compared the variables between two groups of patients, one with microbiologically documented TBM and one with certain non-TBM acute lymphocytic meningitis. The assessed variables had good specificities, but relatively low sensitivities, ruling in the diagnosis of TBM rather than ruling it out. The most reliable predictors in multivariate analysis were: duration of symptoms before admission > 7 days, altered clinical stage, CSF/blood glucose ratio < 0.5 and CSF protein concentration > 200mg/ml. Based on the multivariate model which retained four variables, the probability of TBM in a certain patient could have been increased from 17% to 99.9% when all variables were present, or decreased to 0% when all variables were absent. This study suggests that simple clinical and laboratory features are useful in diagnosing TBM in a high-prevalence region.